[1] Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650-1663.K33帝国网站管理系统
[2] Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.K33帝国网站管理系统
[3] Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term Denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447-455.K33帝国网站管理系统
[4] Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.K33帝国网站管理系统
[5] 洪原城,林平冬,张江灵,刘甲兴,黄种杰.晚期非小细胞肺癌骨转移的骨相关事件及生存分析[J].东南国防医药,2009(2):124-126.K33帝国网站管理系统
[6] Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823-1829.K33帝国网站管理系统
[7] 地舒单抗说明书K33帝国网站管理系统
[8] Kettle JK, Patel PB. Feasibility of extended dosing intervals of denosumab. J Oncol Pharm Pract. 2018;24(5):343-347.K33帝国网站管理系统